• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Xencor Inc.

    3/5/26 4:30:26 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001787397
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Xencor Inc
    SEC File Number
    001-36182
    Address of Issuer
    465 N. HALSTEAD ST.
    SUITE 200
    PASADENA
    CALIFORNIA
    91107
    Phone
    626-305-5900
    Name of Person for Whose Account the Securities are To Be Sold
    Eckert Celia
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    324436480.407333864203/05/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/04/2026Restricted Stock VestingIssuerCheckbox not checked324403/04/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Celia E. Eckert
    465 North Halstead Street
    Suite 200
    Pasadena � CA � 91107
    Common03/03/2026149217747.49

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    03/05/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Gerardo Ibarra-Munoz, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Celia E. Eckert

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $XNCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    10/29/2025$23.00Underweight → Overweight
    Barclays
    9/17/2025$6.00Underweight
    Barclays
    9/3/2025$12.00Buy → Neutral
    BofA Securities
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    More analyst ratings

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Xencor

    Truist initiated coverage of Xencor with a rating of Buy

    11/24/25 8:31:08 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor upgraded by Barclays with a new price target

    Barclays upgraded Xencor from Underweight to Overweight and set a new price target of $23.00

    10/29/25 7:51:01 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Xencor with a new price target

    Barclays resumed coverage of Xencor with a rating of Underweight and set a new price target of $6.00

    9/17/25 8:04:06 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    2/15/24 4:02:46 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the "Licensee") informed Xencor, Inc. (the "Company") that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any future payments for sales in the United States. The Licensee informed the Company that it intends to continue making royalty payments for sales of Ultomiris outside the United States. "Xencor has reasonably assumed that the multiple

    3/4/26 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

    -- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose in ccRCC in 2H26 -- -- Final results from healthy-volunteer study of Xmb942, Xtend™ TL1A antibody, and preclinical characterization of XmAb412, TL1A x IL23p19 XmAb® bispecific antibody, to be presented at DDW 2026 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. "Xen

    2/25/26 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Participate at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT Leerink Partners 2026 Global Healthcare Conference Date: Tuesday, March 10, 2026 Presentation Time: 10:00 a.m. ET / 7:00 a.m. PT Barclays 28th Annual Global Healthcare Conference Date: Wednesday, March 11, 2026 Presentation Time: 11:30 a.m. ET / 8:30 a.m. PT Live webcasts of the presentations will be av

    2/23/26 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SR. VICE PRESIDENT & CSO Desjarlais John R was granted 24,907 shares and sold $31,677 worth of shares (2,663 units at $11.90), increasing direct ownership by 9% to 270,451 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    3/4/26 7:43:59 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SR. VICE PRESIDENT & CFO Cornelissen Bart Jan was granted 19,458 shares, increasing direct ownership by 31% to 81,914 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    3/4/26 7:43:43 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, GENERAL COUNSEL Eckert Celia was granted 18,680 shares and sold $17,747 worth of shares (1,492 units at $11.90), increasing direct ownership by 27% to 81,929 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    3/4/26 7:42:54 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    SEC Filings

    View All

    SEC Form 144 filed by Xencor Inc.

    144 - Xencor Inc (0001326732) (Subject)

    3/5/26 4:30:26 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xencor Inc (0001326732) (Filer)

    3/4/26 4:01:45 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Xencor Inc.

    S-8 - Xencor Inc (0001326732) (Filer)

    2/25/26 4:09:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Financials

    Live finance-specific insights

    View All

    Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

    -- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10:30 a.m. PT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with a

    10/24/25 12:30:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company's website, located at investors.xencor.com. A recording will be available for at l

    10/21/25 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $XNCR
    Leadership Updates

    Live Leadership Updates

    View All

    Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen's capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein desig

    7/31/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Todd Simpson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

    3/13/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Bart Cornelissen as Chief Financial Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

    4/9/24 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 6:16:13 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 1:22:36 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/12/24 4:01:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care